Jpmorgan Chase & CO Kymera Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 140,491 shares of KYMR stock, worth $5.71 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

140,491

Previous 44,944 212.59%

Holding current value

$5.71 Million

Previous $1.34 Million 395.82%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	BUY	$30.16 - $52.4 $2.88 Million - $5.01 Million	95,547 Added 212.59%	140,491 $6.65 Million
Q2 2024 Aug 12, 2024	SELL	$29.85 - $39.42 $12.3 Million - $16.2 Million	-410,992 Reduced 90.14%	44,944 $1.34 Million
Q1 2024 May 10, 2024	SELL	$22.9 - $43.57 $1.29 Million - $2.45 Million	-56,310 Reduced 10.99%	455,936 $18.3 Million
Q4 2023 Feb 12, 2024	SELL	$10.97 - $26.84 $1.2 Million - $2.95 Million	-109,746 Reduced 17.64%	512,246 $13 Million
Q3 2023 Nov 14, 2023	SELL	$13.9 - $23.88 $472,308 - $811,418	-33,979 Reduced 5.18%	621,992 $8.65 Million
Q2 2023 Aug 11, 2023	BUY	$22.4 - $34.92 $1.99 Million - $3.11 Million	89,005 Added 15.7%	655,971 $15.1 Million
Q1 2023 May 18, 2023	BUY	$24.84 - $38.75 $1.19 Million - $1.86 Million	48,044 Added 9.26%	566,966 $16.8 Million
Q1 2023 May 11, 2023	SELL	$24.84 - $38.75 $809,808 - $1.26 Million	-32,601 Reduced 5.91%	518,922 $15.4 Million
Q4 2022 Feb 13, 2023	SELL	$19.57 - $30.92 $202,529 - $319,991	-10,349 Reduced 1.84%	551,523 $13.8 Million
Q3 2022 Nov 14, 2022	SELL	$20.91 - $34.27 $867,890 - $1.42 Million	-41,506 Reduced 6.88%	561,872 $12.2 Million
Q2 2022 Aug 11, 2022	BUY	$14.13 - $42.55 $6.22 Million - $18.7 Million	439,903 Added 269.09%	603,378 $11.9 Million
Q1 2022 May 11, 2022	SELL	$35.3 - $64.68 $605,677 - $1.11 Million	-17,158 Reduced 9.5%	163,475 $6.92 Million
Q4 2021 Feb 10, 2022	BUY	$49.91 - $65.56 $733,577 - $963,600	14,698 Added 8.86%	180,633 $11.5 Million
Q3 2021 Nov 12, 2021	BUY	$47.8 - $66.66 $7.93 Million - $11.1 Million	165,935 New	165,935 $9.75 Million

Others Institutions Holding KYMR

# of Institutions

184

Shares Held

64.4M

Call Options Held

50.6K

Put Options Held

81.7K

View Full List

About Kymera Therapeutics, Inc.

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $2.22B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

More about KYMR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Kymera Therapeutics, Inc. Transaction History